These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 31766720)

  • 41. Novel PARP-1 Inhibitor Scaffolds Disclosed by a Dynamic Structure-Based Pharmacophore Approach.
    Baptista SJ; Silva MM; Moroni E; Meli M; Colombo G; Dinis TC; Salvador JA
    PLoS One; 2017; 12(1):e0170846. PubMed ID: 28122037
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Design of Selective PARP-1 Inhibitors and Antitumor Studies.
    Zhang Y; Li X; Liu F; Bai X; Liu X; Sun H; Gao C; Lin Y; Xing P; Zhu J; Liu R; Wang Z; Dai J; Shi D
    J Med Chem; 2024 Jun; 67(11):8877-8901. PubMed ID: 38776379
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Design, Synthesis and Activity Evaluation of New Phthalazinone PARP Inhibitors.
    Huang M; Ren J; Wang Y; Chen X; Yang J; Tang T; Yang Z; Li X; Ji M; Cai J
    Chem Pharm Bull (Tokyo); 2021; 69(7):620-629. PubMed ID: 34193711
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Synthesis, preliminarily biological evaluation and molecular docking study of new Olaparib analogues as multifunctional PARP-1 and cholinesterase inhibitors.
    Gao CZ; Dong W; Cui ZW; Yuan Q; Hu XM; Wu QM; Han X; Xu Y; Min ZL
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):150-162. PubMed ID: 30427217
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Development of poly ADP-ribose polymerase-1 inhibitor with anti-cervical carcinoma activity.
    Zhang TM; Wang W
    Cell Mol Biol (Noisy-le-grand); 2020 Oct; 66(7):31-34. PubMed ID: 33287919
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Discovery of quinazoline-2,4(1H,3H)-dione derivatives as novel PARP-1/2 inhibitors: design, synthesis and their antitumor activity.
    Zhou J; Ji M; Yao H; Cao R; Zhao H; Wang X; Chen X; Xu B
    Org Biomol Chem; 2018 May; 16(17):3189-3202. PubMed ID: 29648554
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Discovery, mechanism and metabolism studies of 2,3-difluorophenyl-linker-containing PARP1 inhibitors with enhanced in vivo efficacy for cancer therapy.
    Chen W; Guo N; Qi M; Dai H; Hong M; Guan L; Huan X; Song S; He J; Wang Y; Xi Y; Yang X; Shen Y; Su Y; Sun Y; Gao Y; Chen Y; Ding J; Tang Y; Ren G; Miao Z; Li J
    Eur J Med Chem; 2017 Sep; 138():514-531. PubMed ID: 28692916
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Synthesis and
    Guleria M; Kumar A; Singh AK; Kumar P
    Comb Chem High Throughput Screen; 2024; 27(9):1329-1343. PubMed ID: 37691193
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Synthesis of disaccharide nucleoside analogues as potential poly(ADP-ribose) polymerase-1 inhibitors.
    Zheng M; Mex M; Götz KH; Marx A
    Org Biomol Chem; 2018 Nov; 16(46):8904-8907. PubMed ID: 30203829
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A review on PARP1 inhibitors: Pharmacophore modeling, virtual and biological screening studies to identify novel PARP1 inhibitors.
    Singh SS; Sarma JA; Narasu L; Dayam R; Xu S; Neamati N
    Curr Top Med Chem; 2014; 14(17):2020-30. PubMed ID: 25262797
    [TBL] [Abstract][Full Text] [Related]  

  • 51. In Silico Discovery of Novel Flavonoids as Poly ADP Ribose Polymerase (PARP) Inhibitors.
    Shah A; Parmar G; Seth AK
    Curr Comput Aided Drug Des; 2021; 17(3):344-350. PubMed ID: 32268868
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Design, synthesis and biological evaluation of 4-amidobenzimidazole acridine derivatives as dual PARP and Topo inhibitors for cancer therapy.
    Yuan Z; Chen S; Chen C; Chen J; Chen C; Dai Q; Gao C; Jiang Y
    Eur J Med Chem; 2017 Sep; 138():1135-1146. PubMed ID: 28763648
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cytotoxic components from the leaves of Erythrophleum fordii induce human acute leukemia cell apoptosis through caspase 3 activation and PARP cleavage.
    Vo PHT; Nguyen TDT; Tran HT; Nguyen YN; Doan MT; Nguyen PH; Lien GTK; To DC; Tran MH
    Bioorg Med Chem Lett; 2021 Jan; 31():127673. PubMed ID: 33161122
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Discovery of novel benzamide derivatives bearing benzamidophenyl and phenylacetamidophenyl scaffolds as potential antitumor agents via targeting PARP-1.
    Lu G; Nie W; Xin M; Meng Y; Jiang J; Gu J; Cheng X; Chan ASC; Zou Y
    Eur J Med Chem; 2023 May; 251():115243. PubMed ID: 36921527
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Capturing a Pentacyclic Fragment-Based Library Derived from Perophoramidine: Their Design, Synthesis and Evaluation as Anticancer Compounds by DNA Double-Strand Breaks (DSB) and PARP-1 Inhibition.
    Guha S; Yussif El-Deeb I; Yadav S; Das R; Dutta Dubey K; Baruah M; Gremaud L; Sen S
    Chemistry; 2022 Nov; 28(63):e202202405. PubMed ID: 35952312
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Design of potential anti-tumor PARP-1 inhibitors by QSAR and molecular modeling studies.
    Abbasi-Radmoghaddam Z; Riahi S; Gharaghani S; Mohammadi-Khanaposhtanai M
    Mol Divers; 2021 Feb; 25(1):263-277. PubMed ID: 32140890
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
    Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH
    Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Strategies Employed for the Development of PARP Inhibitors.
    Canan S; Maegley K; Curtin NJ
    Methods Mol Biol; 2017; 1608():271-297. PubMed ID: 28695516
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Stepwise development of structure-activity relationship of diverse PARP-1 inhibitors through comparative and validated in silico modeling techniques and molecular dynamics simulation.
    Halder AK; Saha A; Saha KD; Jha T
    J Biomol Struct Dyn; 2015; 33(8):1756-79. PubMed ID: 25350685
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Discovery of Pamiparib (BGB-290), a Potent and Selective Poly (ADP-ribose) Polymerase (PARP) Inhibitor in Clinical Development.
    Wang H; Ren B; Liu Y; Jiang B; Guo Y; Wei M; Luo L; Kuang X; Qiu M; Lv L; Xu H; Qi R; Yan H; Xu D; Wang Z; Huo CX; Zhu Y; Zhao Y; Wu Y; Qin Z; Su D; Tang T; Wang F; Sun X; Feng Y; Peng H; Wang X; Gao Y; Liu Y; Gong W; Yu F; Liu X; Wang L; Zhou C
    J Med Chem; 2020 Dec; 63(24):15541-15563. PubMed ID: 33264017
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.